Compare Panacea Biotech with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs CIPLA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH CIPLA PANACEA BIOTECH/
CIPLA
 
P/E (TTM) x 9.0 29.4 30.8% View Chart
P/BV x 3.5 4.2 84.9% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PANACEA BIOTECH   CIPLA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
CIPLA
Mar-20
PANACEA BIOTECH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs354586 60.4%   
Low Rs138357 38.7%   
Sales per share (Unadj.) Rs74.6207.0 36.0%  
Earnings per share (Unadj.) Rs6.718.6 35.9%  
Cash flow per share (Unadj.) Rs15.533.2 46.7%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs57.2195.5 29.3%  
Shares outstanding (eoy) m61.25806.35 7.6%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x3.32.3 144.9%   
Avg P/E ratio x36.825.3 145.3%  
P/CF ratio (eoy) x15.914.2 111.7%  
Price / Book Value ratio x4.32.4 178.3%  
Dividend payout %021.5 0.0%   
Avg Mkt Cap Rs m15,061379,912 4.0%   
No. of employees `0002.325.8 9.0%   
Total wages/salary Rs m1,47130,270 4.9%   
Avg. sales/employee Rs Th1,973.66,459.6 30.6%   
Avg. wages/employee Rs Th635.61,171.2 54.3%   
Avg. net profit/employee Rs Th176.8580.2 30.5%   
INCOME DATA
Net Sales Rs m4,567166,949 2.7%  
Other income Rs m453,442 1.3%   
Total revenues Rs m4,612170,391 2.7%   
Gross profit Rs m2,03032,060 6.3%  
Depreciation Rs m54011,747 4.6%   
Interest Rs m1,0481,974 53.1%   
Profit before tax Rs m48621,782 2.2%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m776,312 1.2%   
Profit after tax Rs m40914,995 2.7%  
Gross profit margin %44.419.2 231.4%  
Effective tax rate %15.929.0 54.7%   
Net profit margin %9.09.0 99.7%  
BALANCE SHEET DATA
Current assets Rs m2,415117,038 2.1%   
Current liabilities Rs m9,07743,931 20.7%   
Net working cap to sales %-145.943.8 -333.2%  
Current ratio x0.32.7 10.0%  
Inventory Days Days6596 68.0%  
Debtors Days Days7185 83.4%  
Net fixed assets Rs m8,333107,424 7.8%   
Share capital Rs m611,613 3.8%   
"Free" reserves Rs m3,443156,018 2.2%   
Net worth Rs m3,504157,630 2.2%   
Long term debt Rs m46123,693 1.9%   
Total assets Rs m13,755236,626 5.8%  
Interest coverage x1.512.0 12.2%   
Debt to equity ratio x0.10.2 87.6%  
Sales to assets ratio x0.30.7 47.1%   
Return on assets %10.67.2 147.7%  
Return on equity %11.79.5 122.7%  
Return on capital %38.712.8 301.4%  
Exports to sales %20.933.0 63.2%   
Imports to sales %8.10-   
Exports (fob) Rs m95455,175 1.7%   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,20356,036 2.1%   
Fx outflow Rs m4676,764 6.9%   
Net fx Rs m73649,272 1.5%   
CASH FLOW
From Operations Rs m1,04930,685 3.4%  
From Investments Rs m-541,040 -5.1%  
From Financial Activity Rs m-1,011-29,488 3.4%  
Net Cashflow Rs m-202,340 -0.8%  

Share Holding

Indian Promoters % 74.5 16.0 465.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.6 12.2 4.9%  
FIIs % 1.3 23.7 5.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 23.6 26.2 90.1%  
Shareholders   10,259 161,166 6.4%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   CADILA HEALTHCARE  TTK HEALTHCARE  NEULAND LABS  DISHMAN PHARMA  J.B.CHEMICALS  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 447 Points Higher; Automobile & IT Stocks Rally(Closing)

Indian share markets witnessed buying interest during closing hours and ended today's volatile session higher.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Mar 2, 2021 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS